LaQuisa Hill, MD, on Manufacturing a CAR-T with TKIs for T-Cell ALL

LaQuisa Hill, MD, of the Baylor College of Medicine, discusses her research on the antitumor activity of CD5 chimeric antigen receptor (CAR) T cells manufactured with tyrosine kinase inhibitors in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

Dr. Hill and colleagues presented their research on the CAR-T manufacturing approach during the 2023 American Society of Clinical Oncology Annual Meeting.